Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in Cancer
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in Cancer Natick, Mass. October 31st, 2012 Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces the publication of several articles
View HTML
Toggle Summary Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in Cancer
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in Cancer Natick, Mass. October 31st, 2012 Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces the publication of several articles
View HTML
Toggle Summary Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers Natick, Mass. July 25, 2012 Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced dosing of
View HTML
Toggle Summary Karyopharm Therapeutics Announces Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid Tumor Models at the American Society of Clinical Oncology (ASCO) Meeting
Karyopharm Therapeutics Announces Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid Tumor Models at the American Society of Clinical Oncology (ASCO) Meeting Natick, Mass. May 25, 2012 Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators,
View HTML
Toggle Summary Karyopharm Therapeutics Announces Appointment of Cofounder Dr. Ronald DePinho to the National Academy of Sciences
Karyopharm Therapeutics Announces Appointment of Cofounder Dr. Ronald DePinho to the National Academy of Sciences Natick, Mass. May 8, 2012 Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces that co-founder Ronald A.
View HTML
Toggle Summary Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting Natick, Mass. March 15, 2012 Karyopharm Therapeutics
View HTML
Toggle Summary Karyopharm Therapeutics Announces Presentations by Seven Collaborators showing Major Progress in advancing Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at American Society of Hematology (ASH) Meeting.
Collaborators making two oral and five poster presentations on Company’s Lead Oral SINE CRM1 Antagonist program.
View HTML
Toggle Summary Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
Company also moving transport modulators into inflammatory and dermatologic conditions
View HTML
Toggle Summary Karyopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
Karyopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors Karyopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
View HTML
Toggle Summary Multiple Myeloma Research Foundation (MMRF) Invests $3 Million in Development of Next-Generation Treatments
MMRF Biotech Investment Awards Provide Funding to Industry to Advance Myeloma Therapies
View HTML